بيوجين

بيوجين
النوع	عامة
رمز التداول	NASDAQ: BIIB ; NASDAQ-100 component; S&P 100 component; S&P 500 component;
الصناعة	التكنولوجيا الحيوية
المقر الرئيسي	كمبردج، مساتشوستس، الولايات المتحدة
أشخاص رئيسيون	ستليوس پاپادوپولوس (الرئيس) ; مايكل ڤوناتسوس (المدير التطبيقي)
المنتجات	ألپروليكس، أڤونكس، إلوكتيت فامپيرا، گازيڤا، پلگريدي، ريتوكسان، تسفيدارا، تسياباري، سپينرازا
الدخل	▲ 12.274 بليون دولار (2017)
ربح العمليات	▲ 5.344 بليون دولار (2017)
الدخل الصافي	2.539 بليون دولار (2017)
إجمالي الأصول	▲ 23.653 بليون دولار (2017)
إجمالي الأنصبة	▲ 12.613 بليون دولار (2017)
الموظفون	~7.300 (ديسمبر 2017)
المسقط الإلكتروني	biogen.com
	Footnotes / references; *Commercialized by Genentech/Roche

بيوجين Biogen (كانت تُعهد باسم بيوجين آيدك)، هي شركة تكنولوجيا حيوية أمريكية متعددة الجنسيات مقرها كمبردج، مساتشوستس، متخصصة في اكتشاف وتطوير وتوفير الأدوية لعلاج الأمراض العصبية للسقمى حول العالم.

التاريخ

التمويل

السنة	العائد بالمليون USD$	صافي الربح بالمليون USD$	إجمالي الأصول بالمليون USD$	ثمن السهم بالمليون USD$	الموظفون
2005	2.423	161	8.382	39.89
2006	2.683	218	8.553	42.39
2007	3.172	638	8.629	52.16
2008	4.098	783	8.479	51.09
2009	4.377	970	8.552	45.11
2010	4.716	1.005	8.092	51.95
2011	5.049	1.234	9.050	84.78
2012	5.516	1.380	10.130	125.83
2013	6.932	1.862	11.863	198.43	6.850
2014	9.703	2.935	14.315	293.10	7.550
2015	10.764	3.547	19.505	324.99	7.350
2016	11.449	3.703	22.877	258.27	7.400
2017	12.274	2.539	23.653	289.19	7.300

المنتجات

العلاج	الاستخدام (في الولايات المتحدة ما لم يشر لغير ذلك)	سنة الموافقة (US)	سنة الموافقة (EU)	معلومات إضافية
ALPROLIX™ [Coagulation Factor IX (Recombinant), Fc Fusion Protein]	Control and prevention of bleeding episodes, perioperative management and routine prophylaxis in adults and children with hemophilia B	2014	1993	Also approved in Canada and Australia. Biogen and Swedish Orphan Biovitrum (Sobi) are collaborators in the development and commercialization of ALPROLIX.
AVONEX® (interferon beta-1a)	Relapsing forms of multiple sclerosis	1996	1997	Includes the AVONEX PEN auto-injector and the AVOSTARTGRIP titration kit approved in the U.S. in 2012.
ELOدعوة للعملTE™ [Antihemophilic Factor (Recombinant), Fc Fusion Protein]	Control and prevention of bleeding episodes, perioperative (surgical) management and routine prophylaxis in adults and children with hemophilia A	2014	1999	Biogen and Swedish Orphan Biovitrum (Sobi) are collaborators in the development and commercialization of ELOدعوة للعملTE.
FAMPYRA (prolonged-release fampridine tablets)	Multiple sclerosis (Walking ability)	2010	2011	Marketed by Biogen in markets outside of the United States. Commercialized in the United States as AMPYRA (dalfampridine) Extended Release Tablets, by Acorda Therapeutics.
FUMADERM (fumaric acid esters)	Psoriasis German use		1994 (Germany only)	Approved in Germany. Acquired in acquisition of Fumapharm AG in 2006.
GAZYVA (obinutuzumab)	Chronic lymphocytic leukemia	2013	2014	The first medicine approved with the FDA's Breakthrough Therapy Designation and is also currently in Phase ثلاثة trials for NHL and diffuse large B-cell lymphoma. Currently commercialized in the United States by Genentech, a wholly owned subsidiary of Roche.
SPINRAZA (nusinersen)	Spinal muscular atrophy	2016	2017	The first drug approved for the treatment of spinal muscular atrophy, developed in collaboration with Ionis Pharmaceuticals.
PLEGRIDY (peginterferon beta-1a)	Relapsing forms of multiple sclerosis	2014	2014
RITUXAN (rituximab)	Non-Hodgkin's Lymphoma (NHL) Anti-TNF Refractory Rheumatoid Arthritis ANCA-Associated Vasculitis Chronic lymphocytic leukemia	1997 2006 2011	1998 (as MabThera)	The first monoclonal antibody for cancer developed by IDEC, prior to merging with Biogen. Currently commercialized by Roche and its subsidiary, Genentech.
TECFIDERA (dimethyl fumarate)	Relapsing forms of multiple sclerosis	2013	2014
TYSABRI (natalizumab)	Relapsing-remitting multiple sclerosis	2004 Re-introduced in 2006	2006	Full rights purchased from partner Elan in 2013.

المصادر

^ "Biogen Inc. 2017 Annual Report (Form 10-K)". sec.gov. U.S. Securities and Exchange Commission. January 2018.
^ "Does Biogen Idec Inc Have a New Blockbuster Hemophilia Therapy?". The Motley Fool. Retrieved 2014-07-04.
^ "Avonex". National MS Society.
^ "Biogen Idec's Eloctate gains FDA approval". The Pharma Letter. Retrieved 2014-09-06.
^ "Fampridine (Fampyra)". MS Trust.
^ "Biogen Idec enters deal to acquire Fumapharm". First Word Pharma. Retrieved 2006-05-31.
^ "FDA approves Gazyva for chronic lymphocytic leukemia". FDA.gov. Retrieved 2013-01-11.
^ Wadman, Meredith (23 December 2016). "Updated: FDA approves drug that rescues babies with fatal neurodegenerative disease". Science.
^ Grant, Charley (2016-12-27). "Surprise Drug Approval Is Holiday Gift for Biogen". Wall Street Journal. ISSN 0099-9660. Retrieved 2016-12-27.
^ "Biogen Idec's PLEGRIDY(Peginterferon Beta-1a) Approved in the US for the Treatment of Multiple Sclerosis". Reuters.
^ "Biogen Idec's Plegridy approved in Europe for relapsing-remitting multiple sclerosis". The Pharma Letter.
^ "FDA Approval for Rituximab". National Cancer Institute.
^ "UPDATE 1-Roche, Biogen end dispute over Rituxan follow-ons". Reuters. Retrieved 2010-10-21.
^ "FDA approves Rituxan to treat two rare disorders". FDA.gov. Retrieved 2011-04-19.
^ "Cell Therapeutics buys Zevalin from Biogen Idec for $10M, with up to $20M extra plus milestones". The Pharma Letter. Retrieved 2007-09-03.
^ "Tecifedra". National MS Society.
^ "Tysabri". National MS Society.